DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 022244
NDA 022244 describes LUSEDRA, which is a drug marketed by Eisai Inc and is included in one NDA. There is one patent protecting this drug. Additional details are available on the LUSEDRA profile page.
The generic ingredient in LUSEDRA is fospropofol disodium. Additional details are available on the fospropofol disodium profile page.
The generic ingredient in LUSEDRA is fospropofol disodium. Additional details are available on the fospropofol disodium profile page.
Summary for 022244
| Tradename: | LUSEDRA |
| Applicant: | Eisai Inc |
| Ingredient: | fospropofol disodium |
| Patents: | 1 |
Generic Entry Opportunity Date for 022244
Generic Entry Date for 022244*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | 1050MG/30ML (35MG/ML) | ||||
| Approval Date: | Dec 12, 2008 | TE: | RLD: | No | |||||
| Patent: | Start Trial | Patent Expiration: | Jul 1, 2022 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patented Use: | SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION | ||||||||
Expired US Patents for NDA 022244
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eisai Inc | LUSEDRA | fospropofol disodium | SOLUTION;INTRAVENOUS | 022244-001 | Dec 12, 2008 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
